. Author manuscript; available in PMC: 2023 Mar 18.

Published in final edited form as: Med Decis Making. 2022 Dec 13;43(3):337–349. doi: 10.1177/0272989X221143058

Table 3.

Net benefit (NB) estimation for each strategy on the multiple sclerosis example: ‘treat none’, ‘treat all patients with glatiramer acetate’, ‘treat all patients with dimethyl fumarate’, ‘treat all patients with natalizumab’, and ‘treat patients according to the prediction model’. The threshold values used for the NB estimation are: T_GA = T_DF = 10% and T_N = 20% respectively.

	Treat all with				Treat according to the model
	Placebo (‘treat none’)	Glatiramer acetate	Dimethyl fumarate	Natalizumab	Placebo (‘treat none’)	Glatiramer acetate	Dimethyl fumarate	Natalizumab	Total
Treatment rate	0%	100%	100%	100%	4/652=0.6%	0/652=0%	418/652=64.1%	230/652=35.3%	100%
RR from congruent dataset	-	0.68	0.59	0.52	-	-	0.24	0.40
Event rate	${\hat{ε}}_{0} = 53 %$	${\hat{ε}}_{1} = 36 %$	${\hat{ε}}_{2} = 31 %$	${\hat{ε}}_{3} = 28 %$	${\hat{ε}}_{s, 0} = 75 %$	–	${\hat{ε}}_{s, 2} = 18 %$	${\hat{ε}}_{s, 3} = 30 %$	${\hat{ε}}_{s} = 23 %$
Decrease in event rate	0	17%	22%	25%			30%
Net strategy Benefit	0	NB₁ = 0.07	NB₂ = 0.12	NB₃ = 0.05			NB_model = 0.17

RR: Risk ratio